Jump to main content
Jump to site search


C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?

Author affiliations

Abstract

Type 1 diabetes is associated with such complications as blindness, kidney failure, and nerve damage. Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications. Interestingly, after nearly 30 years of positive research results, C-peptide is still not being co-administered with insulin to diabetic patients. The following review discusses the potential of C-peptide as an auxilliary replacement therapy and why it's not currently being used as a therapeutic.

Graphical abstract: C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?

Back to tab navigation

Publication details

The article was received on 04 Apr 2017, accepted on 30 Jun 2017 and first published on 30 Jun 2017


Article type: Review Article
DOI: 10.1039/C7MB00199A
Citation: Mol. BioSyst., 2017, Advance Article
  •   Request permissions

    C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?

    C. W. Pinger, K. E. Entwistle, T. M. Bell, Y. Liu and D. M. Spence, Mol. BioSyst., 2017, Advance Article , DOI: 10.1039/C7MB00199A

Search articles by author

Spotlight

Advertisements